Acura Pharmaceuticals, Inc. 

(Public, NASDAQ:ACUR)   Watch this stock   
Find more results for ACUR

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin -489.36% 32.57%
Operating margin -491.34% 47.22%
EBITD margin - 47.54%
Return on average assets -44.50% 32.68%
Return on average equity -49.09% 51.89%
Employees 15 -

Address

616 N. North Court Suite 120
Palatine, IL 60067
United States - Map
+1-847-7057709 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance

Acura Pharmaceuticals, Inc. discussions

  View all discussions »

Description

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in research, development and manufacture of product candidates providing abuse deterrent features and benefits utilizing its Aversion Technology. The Company’s Aversion Technology platform has been successfully utilized in developing multiple opioid analgesic products candidates. Its portfolio of product candidates includes opioid analgesics to relieve pain while simultaneously discouraging common methods of pharmaceutical product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules, and intentional swallowing of excess quantities of tablets or capsules. Acurox is an orally administered immediate release tablet containing oxycodone HCl as its sole active analgesic ingredient.

Officers and directors

Andrew D. Reddick
President, Chief Executive Officer, Director
Age: 56
Bio & Compensation - Reuters
Peter A. Clemens
Chief Financial Officer, Senior Vice President, Secretary
Portrait. Age: 56
Bio & Compensation - Reuters
Robert B. Jones
Chief Operating Officer, Senior Vice President
Age: 50
Bio & Compensation - Reuters
Robert A. Seiser
Vice President, Corporate Controller and Treasurer
Age: 45
Bio & Compensation - Reuters
Albert W. Brzeczko Ph.D.
Vice President -Technical Affairs
Age: 52
Bio & Compensation - Reuters
Garth Boehm Ph.D.
Vice President - Modified Release Dosage Form Development
Age: 59
Bio & Compensation - Reuters
James F. Emigh
Vice President - Marketing and Administration
Portrait. Age: 53
Bio & Compensation - Reuters
Richard J. Markham
Non-Executive Chairman of the Board
Age: 58
Bio & Compensation - Reuters
William G. Skelly
Director
Age: 58
Bio & Compensation - Reuters
William A. Sumner
Director
Age: 71
Bio & Compensation - Reuters